Telix Pharmaceuticals Limited (TLPPF)
Chart Events
Performance Outlook
| Previous Close | 5.0000 |
| Open | 4.9150 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 4.9150 - 4.9150 |
| 52 Week Range | 2.6900 - 5.6700 |
| Volume | |
| Avg. Volume | 961 |
| Market Cap | 1.557B |
| Beta (5Y Monthly) | 2.45 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.1980 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for TLPPF
Related Research
- TELIX PHARMACEUTICDaily – Vickers Top Buyers & Sellers for 10/14/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic Moat4 months agoArgus Research
- PR Newswire
Telix Reports Fourth Quarter 2022 Financial Results
18 January 2023. Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today issues its Appendix 4C quarterly cash flow statement and accompanying Activities Report for the quarter ended 31 December 2022 (Q4 2022). All figures are in AUD$ unless otherwise stated1 and provided on an unaudited basis.
- PR Newswire
Presentation to J.P. Morgan Healthcare Conference and Q4 2022 Illuccix Revenue Update
Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today advises it is presenting at the 41st Annual J.P. Morgan Healthcare Conference (9 – 12 January) in San Francisco.
- PR Newswire
ZIRCON Phase III Renal Cancer Study to be Presented at ASCO GU along with Theranostic Pipeline Advances
Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the completed pivotal Phase III ZIRCON study (ClinicalTrials.gov Identifier: NCT03849118) of TLX250-CDx (89Zr-DFO-girentuximab) in clear cell renal cell carcinoma (ccRCC) has been selected for oral presentation at the upcoming 2023 ASCO GU Symposium to be held in San Francisco, CA, from February 16-18 2023.
